FOLFOX vs. FOLFIRI in Colorectal Adenocarcinoma: A Retrospective Study of Treatment Patterns, Side Effects, and Treatment Response
DOI:
https://doi.org/10.37275/bsm.v9i3.1221Keywords:
Chemotherapy, Colorectal adenocarcinoma, FOLFIRI, FOLFOX, Retrospective studyAbstract
Background: Colorectal adenocarcinoma (CRC) is a prevalent malignancy with a high recurrence rate, necessitating multimodal treatment strategies. Chemotherapy regimens like FOLFOX (folinic acid, fluorouracil, oxaliplatin) and FOLFIRI (folinic acid, fluorouracil, irinotecan) are crucial components of this approach. This study aimed to analyze treatment patterns, side effects, and treatment response of FOLFOX and FOLFIRI in a real-world cohort of CRC patients.
Methods: A retrospective observational study was conducted on CRC patients who received FOLFOX or FOLFIRI between January 2020 and December 2023. Data on demographics, disease stage, chemotherapy regimen, side effects, comorbidities, and treatment response were collected from electronic medical records.
Results: A total of 146 patients were included. The majority were male (57.5%) with a mean of age 58.4 years. Most tumors were located in the rectum and sigmoid (75.3%), with over 50% of patients presenting with stage IV disease. FOLFIRI was the most common regimen (45.9%), followed by FOLFOX (36.3%). Common side effects included nausea, vomiting, decreased appetite, and hair loss. Hypertension was the most prevalent comorbidity. A total of 79.5% of patients were alive after chemotherapy.
Conclusion: This study provides insights into the real-world treatment patterns and outcomes of FOLFOX and FOLFIRI in CRC patients. The choice of regimen appears to be influenced by factors such as disease stage and patient characteristics. Further research is needed to compare the efficacy and safety of these regimens and identify optimal treatment strategies for specific patient subgroups.
Authors
- Putu Ananda Sutiksna Mulya1*
- Bagus Komang Satriyasa1
- Ni Wayan Sucindra Dewi1
- Desak Ketut Ernawati1
- 1Bachelor of Medicine Study Program, Universitas Udayana, Denpasar, Indonesia
Corresponding author Putu Ananda Sutiksna Mulya — putuananda31@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
